PhaseBio Pharmaceuticals Stock Price - PHAS

0.085 (1.69%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
PhaseBio Pharmaceuticals Inc PHAS NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.085 1.69% 5.125 4.79 5.205 5.08 5.04 13:07:07
Bid Price Ask Price Spread Spread % News
5.11 5.14 0.03 0.58% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,272 407,152 $ 4.96 $ 2,021,335 1,097,140 2.60 - 14.27
Last Trade Time Type Quantity Stock Price Currency
13:07:07 305 $ 5.125 USD

PhaseBio Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 147.50M 28.78M 28.61M $ 2.36M $ - -1.43 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 10.00 0.60%

more financials information »

PhaseBio Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PHAS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.006.354.505.58990,926-0.875-14.58%
1 Month5.128.053.915.811,490,2010.0050.1%
3 Months2.868.052.605.17663,2432.2779.2%
6 Months3.268.492.605.36592,6301.8757.21%
1 Year11.2514.272.605.51421,780-6.13-54.44%
3 Years5.0017.522.556.72354,9380.1252.5%
5 Years5.0017.522.556.72354,9380.1252.5%

PhaseBio Pharmaceuticals Description

PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension.

Your Recent History
PhaseBio P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.